Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 5:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 148 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Asthma, Allergic Clear all
Active, not recruiting Phase 2 Interventional

Dupilumab Effects Against Aeroallergen Challenge

NCT05720325
View directory record Official record
Conditions
Asthma, Allergic
Interventions
Dupilumab, House Dust Mites (HDM), Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 15, 2026, 5:06 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Genetics of Asthma - Bronchoscopy Studies

NCT00644514
View directory record Official record
Conditions
Atopic Asthma, Healthy
Interventions
Endotoxin - lipopolysaccharide (LPS)
Biological
Lead sponsor
John Sundy
Other
Eligibility
18 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Sep 15, 2026, 5:06 PM EDT
Completed No phase listed Observational

Functional Activity of Airway Eosinophils in Allergic Disease

NCT01026532
View directory record Official record
Conditions
Asthma
Interventions
Segmental Allergen Challenge
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 15, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional Results available

Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201

NCT02075008
View directory record Official record
Conditions
Asthma
Interventions
QGE031
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 76 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Evansville, Indiana • Owensboro, Kentucky • Waldorf, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 15, 2026, 5:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Audio Data Collection for Identification and Classification of Coughing

NCT04326309
View directory record Official record
Conditions
COVID-19, Coronavirus Infections, Hay Fever, Asthma, Chronic Obstructive Pulmonary Disease, Influenza, Common Cold, Respiratory Tract Infections, Healthy
Interventions
Not listed
Lead sponsor
HealthMode Inc.
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 15, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies

NCT00599872
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Standardized Ragweed Allergenic Extract, Placebo
Biological
Lead sponsor
Greer Laboratories
Industry
Eligibility
18 Years to 50 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
30
States / cities
Normal, Illinois • Evansville, Indiana • Iowa City, Iowa + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 15, 2026, 5:06 PM EDT
Withdrawn Phase 2 Interventional

CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids

NCT02087644
View directory record Official record
Conditions
Asthma
Interventions
CYT003, Placebo
Biological
Lead sponsor
Cytos Biotechnology AG
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 15, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Results available

Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils

NCT02023151
View directory record Official record
Conditions
Allergic Asthma
Interventions
Omalizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 15, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Results available

Study Of Allergic Rhinitis In Patients Who Also Have Asthma

NCT00296491
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol (FSC), montelukast (MON), fluticasone propionate (FP), placebo nasal, ADVAIR DISKUS, placebo capsule, placebo DISKUS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years and older
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
104
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 15, 2026, 5:06 PM EDT
Completed No phase listed Observational

Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.

NCT05424523
View directory record Official record
Conditions
Allergic Asthma
Interventions
Omalizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Sep 15, 2026, 5:06 PM EDT
Completed No phase listed Observational

Assessing Risk of Food Insecurity Within Households of Children With Food Allergy

NCT01897506
View directory record Official record
Conditions
Food Allergy, Asthma, Allergic Rhinitis, Atopic Dermatitis, Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
1 Year to 17 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Sep 15, 2026, 5:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS

NCT02104505
View directory record Official record
Conditions
Mild, Allergic Asthma
Interventions
Gamma Tocopherol 700 mg capsules,, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 15, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

NCT00267202
View directory record Official record
Conditions
Allergic Asthma
Interventions
Placebo, Omalizumab, Immunotherapy
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 13, 2016 · Synced Sep 15, 2026, 5:06 PM EDT
Terminated Not applicable Interventional

Soluble CD23 Expression in Asthma Patients Treated With OMA

NCT00226200
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 30, 2008 · Synced Sep 15, 2026, 5:06 PM EDT
Completed No phase listed Observational

The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis

NCT01318954
View directory record Official record
Conditions
Allergic Asthma, Allergic Rhinitis
Interventions
Allergen immunotherapy
Biological
Lead sponsor
Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 15, 2026, 5:06 PM EDT
Completed Phase 4 Interventional

Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

NCT00691873
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Xolair
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Sep 15, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional

Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

NCT05667662
View directory record Official record
Conditions
ABPA
Interventions
Itraconazole Powder, Placebo
Drug
Lead sponsor
Pulmatrix Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 15, 2026, 5:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography

NCT00001759
View directory record Official record
Conditions
Asthma, Hypersensitivity, Lung Diseases, Wegener's Granulomatosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 15, 2026, 5:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)

NCT00829985
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial, Asthma
Interventions
Glycerinated German Cockroach Allergenic Extract, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Denver, Colorado • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 15, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

NCT01673672
View directory record Official record
Conditions
Moderate to Severe Allergic Asthma
Interventions
CYT003, Placebo
Biological
Lead sponsor
Cytos Biotechnology AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Los Angeles, Huntington Beach, San Jose, California • Walnut Creek, San Diego, Riverside, Fountain Valley, California • Colorado Springs, Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 15, 2026, 5:06 PM EDT
Recruiting Phase 2 Interventional

5HTP Regulation Of Asthma In Children

NCT04160910
View directory record Official record
Conditions
Mild or Moderate Asthma With Allergic Sensitization
Interventions
5-Hydroxytryptophan, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 15, 2026, 5:06 PM EDT
Completed Phase 2 Interventional

Dose Finding Study for QAW039 in Asthma

NCT01437735
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Montelukast, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Scottsdale, Arizona • Encinitas, California • Huntington Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 15, 2026, 5:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Subcutaneous Immunotherapy for Mouse in Adults

NCT02532179
View directory record Official record
Conditions
Asthma, Perennial Allergic Rhinitis
Interventions
Mouse Allergenic Extract
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 15, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma

NCT00829179
View directory record Official record
Conditions
Allergic Asthma
Interventions
RhuMab-E25
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 15, 2026, 5:06 PM EDT